A phase 1 study assessing the pharmacodynamic effects of VX-150, a highly selective NaV1.8 inhibitor, in healthy male adults
Latest Information Update: 29 Sep 2021
At a glance
- Drugs VX 150 (Primary)
- Indications Pain
- Focus Pharmacodynamics
- 29 Sep 2021 New trial record
- 06 Aug 2021 Results published in the Pain Medicine